FierceBiotech 3. März 2026 FDA details rationale for rejecting rare disease gene therapy from Regenxbio
FierceBiotech 3. März 2026 MindMaze seeks 'strategic alternatives,' eyes US expansion as 2 board members exit
FierceBiotech 3. März 2026 Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug
FierceBiotech 3. März 2026 AI musculoskeletal imaging medtechs Medimaps and Radiobotics pen merger deal
FierceBiotech 3. März 2026 GLP-1s support heart attack recovery in rodents by relaxing tight blood vessels
FierceBiotech 3. März 2026 HHS bans Claude AI tool as Trump seeks full government blacklisting of Anthropic
FierceBiotech 2. März 2026 Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout
FierceBiotech 2. März 2026 TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio
FierceBiotech 2. März 2026 Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline
FierceBiotech 2. März 2026 BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline
FierceBiotech 2. März 2026 United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition
FierceBiotech 2. März 2026 UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy
FierceBiotech 2. März 2026 Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking sock
FierceBiotech 2. März 2026 Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions
FierceBiotech 28. Feb. 2026 BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
FierceBiotech 27. Feb. 2026 Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates